<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384654</url>
  </required_header>
  <id_info>
    <org_study_id>CR108432</org_study_id>
    <secondary_id>2017-003377-34</secondary_id>
    <secondary_id>54767414ALL2005</secondary_id>
    <nct_id>NCT03384654</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (&gt;=)1 and Less Than or Equal to (&lt;=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma</brief_title>
  <official_title>An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects &gt;=1 and &lt;=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard
      chemotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic
      lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening for eligible participants will be performed within 21 days before administration of
      the study drug. Participants with B-cell ALL/LL will receive treatment until disease
      progression or unacceptable toxicity. Participants with T cell ALL/LL will receive treatment
      for up to 2 cycles. If disease progression is confirmed, then the participant will
      discontinue study treatment, complete the End of Treatment Visit, and enter the Posttreatment
      Period. For those participants who discontinue study drug prior to disease progression,
      disease evaluations will continue to be performed every 4 weeks until subsequent anticancer
      therapy is initiated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 8, 2018</start_date>
  <completion_date type="Anticipated">August 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)</measure>
    <time_frame>Within 2 cycles (each cycle of 28-days)</time_frame>
    <description>Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria is defined as: Less than 5 percent (%) blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Full recovery of peripheral blood counts: Platelets greater than (&gt;)100*10^9/liter (L) and absolute neutrophil count (ANC) &gt;1.0*10^9/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Response (CR) for T-cell ALL</measure>
    <time_frame>End of Cycle 1 (each cycle of 28 days)</time_frame>
    <description>Complete response based on the modified NCCN criteria is defined as: Less than 5% blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Full recovery of peripheral blood counts: Platelets &gt;100*10^9/L and ANC &gt;1.0*10^9/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>ORR is defined as percentage of participants who achieve CR or complete response with only partial hematological recovery (CRi) according to NCCN criteria. NCCN criteria for CR: Less than 5 % blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Full recovery of peripheral blood counts: Platelets (&gt;)100 x10^9/L and ANC &gt;1.0x10^9/L; CRi: Less than 5% blasts in the bone marrow; No evidence of circulating blasts or extramedullary disease; Partial recovery of peripheral blood counts not meeting criteria for CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>EFS is defined as the time from the date of first treatment to the first documented treatment failure (that is [ie], disease progression) or date of relapse from CR or death due to any cause, whichever occurs first. Progressive disease: increase of at least 25% in the absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-Free Survival (RFS)</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>RFS is defined as the time from CR to relapse from CR or death due to any cause, whichever occurs first. Relapse from CR is defined as: Reappearance of leukemia blasts in the peripheral blood or more than (&gt;) 5% blasts in the bone marrow; Reappearance of extramedullary disease or new extramedullary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>OS is defined as the time from the date of first treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Minimal Residual Disease (MRD) Negative</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>Percentage of participants who are MRD negative will be assessed. MRD negative is defined as less than (&lt;) 0.01% abnormal population counts to total event counts when measured by flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Receive an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>The percentage of participants who received an allogeneic HSCT after treatment with daratumumab will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Daratumumab</measure>
    <time_frame>Cohort 1 Cycles 1-9 (each cycle is 28 days); Cohort 2 Cycles 1-2 (each cycle is 28 days)</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) of Daratumumab</measure>
    <time_frame>Cohort 1 Cycles 1-9 (each cycle is 28 days); Cohort 2 Cycles 1-2 (each cycle is 28 days)</time_frame>
    <description>The Cmin is the minimum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Daratumumab Antibodies</measure>
    <time_frame>approximately 3 years</time_frame>
    <description>The incidence of anti-daratumumab antibodies will be assessed as number of participant with anti-daratumumab antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Daratumumab in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Cohort 1 Cycles 1-9 (each cycle is 28 days); Cohort 2 Cycles 1-2 (each cycle is 28 days)</time_frame>
    <description>Concentration of daratumumab in CSF will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Precursor Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.</description>
    <arm_group_label>Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL</arm_group_label>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Participant will receive vincristine 1.5 milligram per meter square (mg/m^2) in cohort 1 and cohort 2.</description>
    <arm_group_label>Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL</arm_group_label>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Participant will receive prednisone 40 mg/m^2 in cohort 1 and cohort 2.</description>
    <arm_group_label>Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL</arm_group_label>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Participant will receive doxorubicin 60 mg/m^2 in cohort 2.</description>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peg-asparaginase</intervention_name>
    <description>Participant will receive peg-asparaginase 2500 units per meter square (U/m^2) in cohort 2.</description>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Participant will receive cyclophosphamide 1 gram per meter square (g/m^2) once in cohort 2.</description>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Participant will receive cytarabine 75 mg/m^2 in cohort 2.</description>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-mercaptopurine</intervention_name>
    <description>Participant will receive 6-mercaptopurine 60 mg/m^2 orally daily in cohort 2.</description>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Participant will receive methotrexate 5 g/m^2 intravenously (IV) in cohort 2.</description>
    <arm_group_label>Cohort 2: T-Cell ALL/LL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) as
             defined by the criteria below:

               1. B-cell cohort: Stage 1; ALL in second or greater relapse or refractory to 2 prior
                  induction regimens with greater than or equal to (&gt;=) 5 percent (%) blasts in the
                  bone marrow and aged 1 to less than (&lt;) 18 years. Stage 2; ALL in second or
                  greater relapse or refractory to 2 prior induction regimens with (&gt;=) 5% blasts
                  in the bone marrow and aged 1 to 30 years. LL in second or greater relapse or
                  refractory to 2 prior induction regimens and biopsy proven and with evidence of
                  measurable disease by radiologic criteria and aged 1 to 30 years.

               2. T-cell cohort: Stage 1; ALL in first relapse or refractory to 1 prior
                  induction/consolidation regimen with (&gt;=) 5% blasts in the bone marrow and aged 1
                  to &lt;18 years. Stage 2; ALL in first relapse or refractory to 1 prior
                  induction/consolidation regimen with (&gt;=) 5% blasts in the bone marrow and aged 1
                  to 30 years. LL in first relapse or refractory to 1 prior induction/consolidation
                  regimen biopsy proven and with evidence of measurable disease by radiologic
                  criteria and aged 1 to 30 years

          -  Performance status greater than or equal to (&gt;=) 70 by Lansky scale (for participants
             less than [&lt;] 16 years of age) or Karnofsky scale (for participants [&gt;=] 16 years of
             age)

          -  Adequate hematology laboratory values at Cycle 1 Day 1 pre-dosing defined as follows:

               1. Hemoglobin (&gt;=) 7.5 gram per deciliter (g/dL) ([&gt;=] 5 millimole per liter
                  [mmol/L]; prior red blood cell [RBC] transfusion is permitted)

               2. Platelet count (&gt;=) 10*10^9 per liter (L) (prior platelet transfusion is
                  permitted)

          -  Adequate renal function defined as normal serum creatinine for the participant's age
             or creatinine clearance or radioisotope glomerular filtration rate (GFR) 70 milliliter
             per minute per 1.73 square meter (mL/min/1.73 m^2) at Cycle 1 Day 1 pre-dosing

          -  Adequate liver function at Cycle 1 Day 1 pre-dosing defined as:

               1. Alanine aminotransferase level less than or equal to (&lt;=) 2.5* the upper limit of
                  normal (ULN),

               2. Aspartate aminotransferase level (&lt;=) 2.5* ULN, and

               3. Total bilirubin (&lt;=) 2* ULN or direct bilirubin level (&lt;=) 2.0* ULN

        Exclusion Criteria:

          -  Received an allogeneic hematopoietic transplant within 3 months of screening

          -  Active acute graft-versus-host disease of any grade or chronic graft-versus-host
             disease of Grade 2 or higher

          -  Received immunosuppression post hematopoietic transplant within 1 month of study entry

          -  Philadelphia chromosome positive (Ph+) B-cell ALL eligible for tyrosine kinase
             inhibitor therapy

          -  Has either of the following:

               1. Evidence of dyspnea at rest or oxygen saturation (&lt;=) 94 percent (%).

               2. Known moderate or severe persistent asthma within the past 2 years, or
                  uncontrolled asthma of any classification

          -  Received an investigational drug, was vaccinated with live attenuated vaccines, or
             used an invasive investigational medical device within 4 weeks before the planned
             first dose of study drug, or is currently being treated in an investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College Of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent - UZ GENT</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux, Hopital des Enfants</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IHOPE - Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital trousseau- APHP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital D'Enfants</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite-Universitätsmedizin Berlin - Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petach Tiquva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione MBBM, ASST Monza</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Sant Joan de Deu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Infantil Univ. Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. I Politecni La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds Children's Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

